Clinical trials: Physical activity
Solid Tumor
Study of AK119 in Subjects With Advanced Solid Tumors
This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.
- Trial name
- NCT05173792
- Testing
- AK119
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Akeso
Pulmonary Disease, Chronic Obstructive
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Study to evaluate the safety of combivent delivered in two different formulations (hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI), using a cumulative dose response model in patients with…
- Trial name
- NCT02182869
- Testing
- Combivent® HFA inhalation aerosol, Combivent® CFC inhalation aerosol
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Post-stroke Aphasia
Neurostimulation for the Treatment of Post-Stroke Aphasia
The aim of the trial is to determine whether 75Hz transcranial alternating current stimulation (tACS) synchronized with therapeutic linguistic tasks is an effective form of therapy for post-stroke aphasia.
- Trial name
- NCT05194566
- Testing
- tACS
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- QVITI S.A.
HIV Infections
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy.
- Trial name
- NCT00002451
- Testing
- Indinavir sulfate, Ritonavir, Lamivudine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
- Trial name
- NCT05964829
- Testing
- Cionic Neural Sleeve NS-100, Walking Program
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cionic, Inc.
Asthma, Exercise-induced
Exercise Induced Bronchoconstriction (0476-359)
Exercise-induced bronchoconstriction (EIB) is a condition where airways tighten when you exercise and may cause coughing, wheezing, or shortness of breath.
- Trial name
- NCT00664937
- Testing
- montelukast sodium
- Volunteers
- 24 people
- Sponsor
- Organon and Co
Prostate Cancer
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.
- Trial name
- ENACT (NCT02799745)
- Testing
- Enzalutamide, Active Surveillance
- Where
- 54 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Diabetes Mellitus
Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus
The Phase 1b study is a multi-center trial designed to test the safety, tolerability, biologic activity of escalating doses of FG-3019 in up to 20 patients with type 1 or type 2 diabetes and microalbuminuria (early-stage kidney…
- Trial name
- NCT00102297
- Testing
- FG-3019
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Kyntra Bio
Cancer of Ovary, Neoplasms, Ovarian
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
This is a Phase Ib study to look at the combination of an antibody immunization vaccine strategy using oregovomab and an investigational stage immune booster (poly ICLC / Hiltonol), both of which have previously been used in…
- Conditions
- Cancer of Ovary, Neoplasms, Ovarian, Ovarian Cancer Stage IV, Ovarian Cancer Recurrent
- Trial name
- NCT03162562
- Testing
- Oregovomab, Poly ICLC
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- CanariaBio Inc.
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in…
- Trial name
- NCT06385327
- Testing
- ABI-5366
- Where
- 15 sites in Australia, New Zealand
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Breast Cancer
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
- Trial name
- NCT05080842
- Testing
- AC682
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Accutar Biotechnology Inc
Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
This is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab, paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal…
- Conditions
- Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV
- Trial name
- NCT04938583
- Testing
- Oregovomab, Bevacizumab, Paclitaxel
- Where
- 6 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- CanariaBio Inc.
Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT04002622
- Testing
- TQB2450
- Where
- 18 sites in China
- Volunteers
- 1 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253.
- Trial name
- NCT02987829
- Testing
- TRC253
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Insomnia
Remote STATE Training for Insomnia in Older Adults
This study called rSTATE (Remote STATE Training for Insomnia in Older Adults) is a Phase II study to definitively evaluate the efficacy of a computerized cognitive training program (rSTATE) designed to improve sleep regulation…
- Trial name
- rSTATE (NCT06589024)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Sleep Hygiene Education
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Posit Science Corporation
Hypercholesterolemia
Open Label Study of Long Term Evaluation Against LDL-C Trial
The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.
- Trial name
- OSLER (NCT01439880)
- Testing
- Evolocumab, Standard of care
- Where
- 187 sites in United States, Australia and 16 more
- Volunteers
- 1,324 people
- Sponsor
- Amgen
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or…
- Trial name
- NCT06132503
- Testing
- LP-284
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Lantern Pharma Inc.
Mild Traumatic Brain Injury
Home-Based, Online, Mindfulness and Cognitive Training for Soldiers and Veterans With TBI
This study is a parallel arm, double-blind, randomized, controlled clinical trial to assess the safety and efficacy of an experimental software program designed to improve cognitive functions versus a computer-based software…
- Trial name
- CogMind (NCT02922569)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Mindfulness Training
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Posit Science Corporation
Pain
Omnitram Pharmacokinetic Study In Healthy Volunteers
The purpose of this study is to compare the safety, pharmacokinetic properties (the absorption, distribution and excretion), and analgesic activity of Omnitram (10 mg tablets), Tramadol (Ultram, 50 mg tablet) following oral…
- Trial name
- NCT02205554
- Testing
- Omnitram, Tramadol
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Syntrix Biosystems, Inc.
Advanced Malignancy
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in combination with tremelimumab in Chinese Patients with Advanced Malignancies
- Trial name
- NCT02978482
- Testing
- durvalumab, tremelimumab + durvalumab
- Where
- 2 sites in China
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.